These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 1979217)

  • 41. Neurotoxicity of the psychedelic amphetamine, methylenedioxymethamphetamine.
    Schmidt CJ
    J Pharmacol Exp Ther; 1987 Jan; 240(1):1-7. PubMed ID: 2433425
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Lack of neurotoxicity after intra-raphe micro-injections of MDMA ("ecstasy").
    Paris JM; Cunningham KA
    NIDA Res Monogr; 1990; 105():333-4. PubMed ID: 1715034
    [No Abstract]   [Full Text] [Related]  

  • 43. (+/-)3,4-Methylenedioxymethamphetamine selectively damages central serotonergic neurons in nonhuman primates.
    Ricaurte GA; Forno LS; Wilson MA; DeLanney LE; Irwin I; Molliver ME; Langston JW
    JAMA; 1988 Jul; 260(1):51-5. PubMed ID: 2454332
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The molecular mechanism of "ecstasy" [3,4-methylenedioxy-methamphetamine (MDMA)]: serotonin transporters are targets for MDMA-induced serotonin release.
    Rudnick G; Wall SC
    Proc Natl Acad Sci U S A; 1992 Mar; 89(5):1817-21. PubMed ID: 1347426
    [TBL] [Abstract][Full Text] [Related]  

  • 45. 5-HT loss in rat brain following 3,4-methylenedioxymethamphetamine (MDMA), p-chloroamphetamine and fenfluramine administration and effects of chlormethiazole and dizocilpine.
    Colado MI; Murray TK; Green AR
    Br J Pharmacol; 1993 Mar; 108(3):583-9. PubMed ID: 7682129
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Treating MDMA ('Ecstasy') toxicity.
    Padkin A
    Anaesthesia; 1994 Mar; 49(3):259. PubMed ID: 7908506
    [No Abstract]   [Full Text] [Related]  

  • 47. 3,4-Methylenedioxy analogues of amphetamine: defining the risks to humans.
    Hegadoren KM; Baker GB; Bourin M
    Neurosci Biobehav Rev; 1999 Mar; 23(4):539-53. PubMed ID: 10073892
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Lasting effects of (+-)-3,4-methylenedioxymethamphetamine (MDMA) on central serotonergic neurons in nonhuman primates: neurochemical observations.
    Ricaurte GA; Martello AL; Katz JL; Martello MB
    J Pharmacol Exp Ther; 1992 May; 261(2):616-22. PubMed ID: 1374470
    [TBL] [Abstract][Full Text] [Related]  

  • 49. 3,4-Methylenedioxymethamphetamine and 3,4-methylenedioxyamphetamine destroy serotonin terminals in rat brain: quantification of neurodegeneration by measurement of [3H]paroxetine-labeled serotonin uptake sites.
    Battaglia G; Yeh SY; O'Hearn E; Molliver ME; Kuhar MJ; De Souza EB
    J Pharmacol Exp Ther; 1987 Sep; 242(3):911-6. PubMed ID: 2443644
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Contribution of serotonin neurotoxins to understanding psychiatric disorders: the role of 5-HT2 receptors in schizophrenia and antipsychotic activity.
    Schmidt CJ; Kehne JH; Carr AA; Fadayel GM; Humphreys TM; Kettler HJ; McCloskey TC; Padich RA; Taylor VL; Sorensen SM
    Int Clin Psychopharmacol; 1993 Nov; 8 Suppl 2():25-32. PubMed ID: 7911139
    [No Abstract]   [Full Text] [Related]  

  • 51. Selective 5-hydroxytryptamine2 receptor antagonists protect against the neurotoxicity of methylenedioxymethamphetamine in rats.
    Schmidt CJ; Abbate GM; Black CK; Taylor VL
    J Pharmacol Exp Ther; 1990 Nov; 255(2):478-83. PubMed ID: 1978728
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effects of MDMA and MDA on brain serotonin neurons: evidence from neurochemical and autoradiographic studies.
    De Souza EB; Battaglia G
    NIDA Res Monogr; 1989; 94():196-222. PubMed ID: 2575225
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Serotonergic neurotoxic metabolites of ecstasy identified in rat brain.
    Jones DC; Duvauchelle C; Ikegami A; Olsen CM; Lau SS; de la Torre R; Monks TJ
    J Pharmacol Exp Ther; 2005 Apr; 313(1):422-31. PubMed ID: 15634943
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Orally administered MDMA causes a long-term depletion of serotonin in rat brain.
    Finnegan KT; Ricaurte GA; Ritchie LD; Irwin I; Peroutka SJ; Langston JW
    Brain Res; 1988 Apr; 447(1):141-4. PubMed ID: 2898273
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [MDMA ("ecstasy"): a currently used drug in Spain].
    Prat A; Montero M; Reig R; Sanz P
    Rev Clin Esp; 1991 Feb; 188(2):106-8. PubMed ID: 1675014
    [No Abstract]   [Full Text] [Related]  

  • 56. Chronic paranoid psychosis after misuse of MDMA ("ecstasy").
    McGuire P; Fahy T
    BMJ; 1991 Mar; 302(6778):697. PubMed ID: 1673631
    [No Abstract]   [Full Text] [Related]  

  • 57. Flashbacks following MDMA.
    McGuire P; Fahy T
    Br J Psychiatry; 1992 Feb; 160():276. PubMed ID: 1347241
    [No Abstract]   [Full Text] [Related]  

  • 58. Risk assessment for neurotoxic effects.
    Gaylor DW; Slikker W
    Neurotoxicology; 1990; 11(2):211-8. PubMed ID: 1700346
    [TBL] [Abstract][Full Text] [Related]  

  • 59. 5-Hydroxyindoleacetic acid in cerebrospinal fluid reflects serotonergic damage induced by 3,4-methylenedioxymethamphetamine in CNS of non-human primates.
    Ricaurte GA; DeLanney LE; Wiener SG; Irwin I; Langston JW
    Brain Res; 1988 Dec; 474(2):359-63. PubMed ID: 2463059
    [TBL] [Abstract][Full Text] [Related]  

  • 60. 5-HT, MDMA (ecstasy), and nimodipine effects on 45Ca-uptake into rat brain synaptosomes.
    Park WK; Azmitia EC
    Ann N Y Acad Sci; 1991; 635():438-40. PubMed ID: 1683755
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.